USNA

USANA Health Sciences Inc. Common Stock (USNA)

Stock · NYSE · Health Care

$15.54as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

USANA in Yahoo warning‑signs article for cash‑producing stocks. Yahoo highlighted USANA as one of three cash‑producing companies showing warning signs. The note points to possible concerns even though the company generates solid cash flow. USANA is currently near its $18.53 support level with an RSI around 44, and analysts still have a $25 price target.

Active signals

Support level
$14.22
Industry
Medicinal Chemicals and Botanical Products

What USNA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike34-4.9%32%
Bollinger Band Breakdown25-2.9%36%
Bollinger Band Breakout23-3.2%35%
200-Day Moving Average TouchActive now8-3.5%25%
Any 20-session window (baseline)-1.4%43%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About USNA

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials,…

Sector
Health Care
Industry
Medicinal Chemicals and Botanical Products
Employees
1,570

Fundamentals

1-day range
$14.48$15.28
Market cap
$274.91M
P/E (trailing)
32.28
P/E (forward)
8.45
EPS (trailing)
$0.48
Dividend yield
—
Beta
0.68
Avg. volume
190.2K
52-week range
$12.57$23.59
Next earnings: November 3, 2026 · EPS estimate $0.11After Closeconfirmed

How USANA Health Sciences Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$925.26MNet Income$10.76M (1%)Other$346.22M (37%)SG&A$337.37M (36%)Cost of Revenue$200.85M (22%)Tax$30.05M (3%)USNA

Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub

Gross Profit$724.40M(78%)
Operating Income$37.43M(4%)

Forecasts

1 analyst ratings

Buy 0%
Hold 50%
Sell 50%
1-year price forecast
High
$25
+60.9%
Median
$25
+60.9%
Low
$25
+60.9%

USANA Health Sciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • USNA
    USANA Health Sciences Inc. Common Stock
    $15.54
    ▲ 1.04%
    Market cap $274.91MP/E 32.28
    $12.57$23.59
  • OBIO
    Orchestra BioMed Holdings Inc. Ordinary Shares
    $5.45
    ▼ 5.05%
    Market cap $248.50MP/E —
    $3.1$6.5
  • NAGE
    Niagen Bioscience Inc. Common Stock
    $2.49
    ▼ 3.49%
    Market cap $240.54MP/E 12.74
    $2.51$7.95
  • SNDL
    SNDL Inc. Common Shares
    $1.25
    ▲ 3.31%
    Market cap $312.36MP/E —
    $1.13$2.57
  • ACB
    Aurora Cannabis Inc. Common Shares
    $3.99
    ▼ 2.68%
    Market cap $184.63MP/E —
    $3.59$8.75
  • MDWD
    MediWound Ltd. Ordinary Shares
    $11.85
    ▼ 2.95%
    Market cap $183.44MP/E —
    $11.9$20.03
  • CGC
    Canopy Growth Corporation Common Shares
    $0.713
    ▼ 3.13%
    Market cap $400.49MP/E —
    $0.995$3.28

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
13.2K
Disposed
3.5K

Institutional Ownership

March 31, 2026

Total shares held
9.75M
Total value held
$166.97M
Institutional holders
132
Top holders this quarter
  • Unknown1.19M
  • Unknown1.11M
  • Unknown1.02M
  • Unknown834.2K
  • Unknown810.1K
  • Unknown479.0K
  • Unknown333.1K
  • Unknown296.4K
  • Unknown264.4K
  • Unknown248.0K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.